- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05208047
(Peak) A Phase 3 Randomized Trial of Bezuclastinib (CGT9486)+Sunitinib vs. Sunitinib in Participants With Gastrointestinal Stromal Tumors
Eine randomisierte, offene, multizentrische klinische Phase-3-Studie zu CGT9486+Sunitinib vs. Sunitinib bei Patienten mit lokal fortgeschrittenen, nicht resezierbaren oder metastasierten gastrointestinalen Stromatumoren
This is a Phase 3, open-label, international, multicenter study of bezuclastinib in combination with sunitinib. This is a multi-part study that will enroll approximately 482 participants. Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of bezuclastinib to be used in subsequent parts in approximately 20 participants who have received at least one prior line of therapy for Gastrointestinal Stromal Tumors (GIST) and 2) evaluating the potential for drug-drug interactions between bezuclastinib and sunitinib in approximately 18 participants who have received at least two prior tyrosine kinase inhibitors (TKIs) for GISTs. The second part of the study will enroll approximately 388 participants who are intolerant to, or who failed prior treatment with imatinib only and will compare the efficacy of bezuclastinib plus sunitinib to sunitinib alone with participants being randomized in a 1:1 manner. This study also contains two substudies: 1) a drug-drug interactions (DDI) substudy will investigate the potential for bezuclastinib to be a Cytochrome P450 (CYP)3A4 inducer in approximately 16 participants who have received at least one prior line of therapy for GIST and 2) a substudy intended to test the efficacy of bezuclastinib and sunitinib as first-line (1L) treatment of GIST in approximately 40 participants with KIT exon 9 mutations and no prior systemic therapy (with the exception of up to 10 participants with ongoing imatinib therapy of ≤4 weeks).
Studienübersicht
Status
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 3
Kontakte und Standorte
Studienkontakt
- Name: Cogent Biosciences
- Telefonnummer: 617-945-5576
- E-Mail: peakinfo@cogentbio.com
Studienorte
-
-
-
Buenos Aires, Argentinien, C1426ANZ
- Aktiv, nicht rekrutierend
- Instituto Alexander Fleming
-
Córdoba, Argentinien, X5000HWE
- Aktiv, nicht rekrutierend
- Instituto Oncologico de Cordoba (IONC)
-
-
-
-
-
Bankstown, Australien, 2200
- Aktiv, nicht rekrutierend
- Bankstown-Lidcombe Hospital
-
-
Western Australia
-
Nedlands, Western Australia, Australien, 6009
- Aktiv, nicht rekrutierend
- Sir Charles Gairdner Hospital
-
-
-
-
-
Campinas, Brasilien, 130.83-888
- Aktiv, nicht rekrutierend
- Hospital das Clinicas da Universidade Estadual de Campinas (UNICAMP)
-
Rio de Janeiro, Brasilien, 20.230-130
- Aktiv, nicht rekrutierend
- lnstituto Nacional de Cancer - INCA
-
São Paulo, Brasilien, 09060-650
- Aktiv, nicht rekrutierend
- CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia
-
-
-
-
-
Santiago, Chile, 7500921
- Aktiv, nicht rekrutierend
- Instituto Oncologico FALP
-
Santiago, Chile, 7560908
- Aktiv, nicht rekrutierend
- Centro de Oncologia de Precision, Universidad Mayor
-
-
-
-
-
Bad Saarow, Deutschland, 15526
- Aktiv, nicht rekrutierend
- Helios Klinikum Bad Saarow
-
Berlin, Deutschland, 13125
- Aktiv, nicht rekrutierend
- Helios Klinikum Berlin-Buch
-
Essen, Deutschland, 45147
- Aktiv, nicht rekrutierend
- Universitaetsklinikum Essen
-
Hamburg, Deutschland, 20246
- Aktiv, nicht rekrutierend
- Universitaetsklinikum Hamburg-Eppendorf
-
Hanover, Deutschland, 30625
- Aktiv, nicht rekrutierend
- Medizinische Hochschule Hannover- Urology Oncology
-
Mannheim, Deutschland, 68167
- Aktiv, nicht rekrutierend
- Universitaetsmedizin Mannheim
-
-
-
-
-
Aarhus, Dänemark, 8200
- Aktiv, nicht rekrutierend
- Aarhus University Hospital
-
-
-
-
-
Bordeaux, Frankreich, 33076
- Aktiv, nicht rekrutierend
- Institut Bergonie
-
Lille, Frankreich, 59000
- Aktiv, nicht rekrutierend
- Centre Oscar Lambret
-
Lyon, Frankreich, 69008
- Aktiv, nicht rekrutierend
- Centre Leon Berard
-
Marseille, Frankreich, 13005
- Aktiv, nicht rekrutierend
- AP-HM - Hôpital de la Timone
-
Rennes, Frankreich, 35042
- Aktiv, nicht rekrutierend
- Centre Eugene Marquis
-
Saint-Herblain, Frankreich, 44800
- Aktiv, nicht rekrutierend
- ICO St-Herblain
-
Toulouse, Frankreich, 31400
- Aktiv, nicht rekrutierend
- CHU de Toulouse - Hospital Rangueil
-
Villejuif, Frankreich, 94805
- Aktiv, nicht rekrutierend
- Gustave Roussy
-
-
-
-
-
Central, Hongkong
- Zurückgezogen
- Humanity & Health Clinical Trial Centre
-
Jordon, Hongkong
- Aktiv, nicht rekrutierend
- Hong Kong United Oncology Centre
-
Shatin, Hongkong
- Aktiv, nicht rekrutierend
- Prince of Wales Hospital
-
-
-
-
-
Aviano, Italien, 33081
- Aktiv, nicht rekrutierend
- Centro Riferimento Oncologico - Aviano
-
Bologna, Italien, 40138
- Aktiv, nicht rekrutierend
- IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola
-
Brescia, Italien, 25123
- Aktiv, nicht rekrutierend
- ASST degli Spedali Civili di Brescia
-
Candiolo, Italien, 10060
- Zurückgezogen
- IRCCS La Fondazione e l'Istituto di Candiolo
-
Florence, Italien, 50134
- Aktiv, nicht rekrutierend
- Azienda Ospedaliero-Universitaria Careggi
-
Meldola, Italien, 47014
- Aktiv, nicht rekrutierend
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
-
Milan, Italien, 20133
- Aktiv, nicht rekrutierend
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Milan, Italien, 20141
- Aktiv, nicht rekrutierend
- Istituto Europeo di Oncologia
-
Palermo, Italien, 90127
- Aktiv, nicht rekrutierend
- Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
-
Roma, Italien, 00128
- Aktiv, nicht rekrutierend
- Policlinico Universitario Campus Bio-Medico
-
Rozzano, Italien, 20089
- Aktiv, nicht rekrutierend
- Istituto Clinico Humanitas
-
Verona, Italien, 31726
- Aktiv, nicht rekrutierend
- Azienda Ospedaliera Universitaria Integrata Verona-Ospedale Borgo Trento
-
-
-
-
-
Calgary, Kanada, T2N 4N2
- Rekrutierung
- Tom Baker Cancer Center
-
Montreal, Kanada, HIT 2M4
- Aktiv, nicht rekrutierend
- Universite de Montreal - Hopital Maisonneuve-Rosemont (HMR)
-
-
Alberta
-
Edmonton, Alberta, Kanada, T6G 1Z2
- Rekrutierung
- Alberta Health Services Cross Cancer Institute
-
-
Ontario
-
Toronto, Ontario, Kanada, M5G 2M9
- Rekrutierung
- Princess Margaret Hospital
-
-
-
-
-
Aguascalientes, Mexiko, 20116
- Zurückgezogen
- Centro de Investigacion Medica Aquascalientes (CIMA)
-
Monterrey, Mexiko, 64710
- Aktiv, nicht rekrutierend
- I Can Oncology Center SA De CV
-
Oaxaca City, Mexiko, 68000
- Zurückgezogen
- Oaxaca Site Management Organization S.C.
-
-
-
-
-
Amsterdam, Niederlande, 1066 CX
- Aktiv, nicht rekrutierend
- Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL)
-
Groningen, Niederlande, 9713 GZ
- Aktiv, nicht rekrutierend
- UMC Groningen
-
Nijmegen, Niederlande, 6525 GA
- Aktiv, nicht rekrutierend
- Stichting Radboud Universitair Medisch Centrum
-
Rotterdam, Niederlande, 3015 GD
- Aktiv, nicht rekrutierend
- Erasmus MC
-
-
-
-
-
Bergen, Norwegen, 5021
- Aktiv, nicht rekrutierend
- Haukeland University Hospital - Bergen
-
Oslo, Norwegen, 0310
- Aktiv, nicht rekrutierend
- Oslo University Hospital
-
-
-
-
-
Brzozów, Polen, 36-200
- Aktiv, nicht rekrutierend
- Szpital Specjalistyczny w Brzozowie
-
Bydgoszcz, Polen, 85-796
- Zurückgezogen
- Centrum Onkologii im. Prof. Franciszka Lukaszczyka
-
Gliwice, Polen, 44-102
- Aktiv, nicht rekrutierend
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Oddzial w Gliwicach, Oddzial Chemioterapii Dziennej
-
Warsaw, Polen, 02-781
- Aktiv, nicht rekrutierend
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Klinika Nowotworow Tkanek Miekkich, Kosci i Czerniakow
-
-
-
-
-
Lund, Schweden, 22185
- Aktiv, nicht rekrutierend
- Skane University Hospital Lund
-
Solna, Schweden, 171 76
- Aktiv, nicht rekrutierend
- Karolinska University Hospital
-
-
-
-
-
Barcelona, Spanien, 08035
- Aktiv, nicht rekrutierend
- Hospital Universitario Vall d'Hebron
-
Barcelona, Spanien, 08041
- Zurückgezogen
- Hospital de la Santa Creu i Sant Pau Barcelona
-
Barcelona, Spanien, 08908
- Aktiv, nicht rekrutierend
- Institut Catala d'Oncologia - L'Hospitalet
-
El Palmar, Spanien, 30120
- Zurückgezogen
- Hospital Clinico Universitario Virgen de la Arrixaca
-
Madrid, Spanien, 28041
- Aktiv, nicht rekrutierend
- Hospital Universitario 12 de Octubre
-
Madrid, Spanien, 28040
- Aktiv, nicht rekrutierend
- Hospital Clinico San Carlos
-
Madrid, Spanien, 28007
- Aktiv, nicht rekrutierend
- Hospital General Universitario Gregorio Maranon
-
Madrid, Spanien, 28040
- Aktiv, nicht rekrutierend
- Hospital Fundación Jiménez Díaz
-
Santiago de Compostela, Spanien, 15706
- Aktiv, nicht rekrutierend
- Hospital Clinico Universitario de Santiago de Compostela
-
Seville, Spanien, 41013
- Aktiv, nicht rekrutierend
- Hospital Universitario Virgen del Rocio
-
Zaragoza, Spanien, 50009
- Zurückgezogen
- Hospital Universitario Miguel Servet
-
-
-
-
-
Seoul, Südkorea, 03080
- Aktiv, nicht rekrutierend
- Seoul National University Hospital
-
Seoul, Südkorea, 06351
- Aktiv, nicht rekrutierend
- Samsung Medical Center
-
Seoul, Südkorea, 08308
- Aktiv, nicht rekrutierend
- Korea University Guro Hospital
-
Seoul, Südkorea, 05505
- Aktiv, nicht rekrutierend
- Asan Medical Center
-
-
Gyeonggi-do
-
Goyang-si, Gyeonggi-do, Südkorea, 10408
- Zurückgezogen
- National Cancer Center
-
-
-
-
-
Kaohsiung City, Taiwan, 83301
- Aktiv, nicht rekrutierend
- Chang Gung Memorial Hospital - Kaohsiung Branch
-
New Taipei City, Taiwan, 10002
- Aktiv, nicht rekrutierend
- National Taiwan University Hospital
-
Taichung, Taiwan, 40447
- Aktiv, nicht rekrutierend
- China Medical University Hospital
-
Taipei, Taiwan, 11217
- Aktiv, nicht rekrutierend
- Taipei Veterans General Hospital (VGHTP)
-
Taoyuan, Taiwan, 33305
- Aktiv, nicht rekrutierend
- Chang Gung Memorial Hospital - Linkou Branch (CGMHLK)
-
-
-
-
-
Brno, Tschechien, 65653
- Aktiv, nicht rekrutierend
- Masarykuv onkologicky ustav
-
Hradec Králové, Tschechien, 500 05
- Zurückgezogen
- Fakultni nemocnice Hradec Kralove
-
Olomouc, Tschechien, 77900
- Aktiv, nicht rekrutierend
- Fakultni nemocnice Olomouc - Oncology clinic
-
-
-
-
-
Debrecen, Ungarn, 4032
- Aktiv, nicht rekrutierend
- Debreceni Egyetem, Klinikai Központ, Onkológiai Klinika
-
-
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten, 35249
- Zurückgezogen
- University of Alabama at Birmingham
-
-
Arizona
-
Scottsdale, Arizona, Vereinigte Staaten, 85259
- Rekrutierung
- Mayo Clinic
-
Tucson, Arizona, Vereinigte Staaten, 85719
- Aktiv, nicht rekrutierend
- University of Arizona- Cancer Center
-
-
California
-
Duarte, California, Vereinigte Staaten, 91010
- Rekrutierung
- City of Hope
-
Los Angeles, California, Vereinigte Staaten, 90404
- Aktiv, nicht rekrutierend
- University of California, Los Angeles (UCLA)
-
San Diego, California, Vereinigte Staaten, 92093
- Rekrutierung
- University of California, San Diego (UCSD)
-
San Francisco, California, Vereinigte Staaten, 94158
- Aktiv, nicht rekrutierend
- University of California, San Francisco
-
-
Colorado
-
Denver, Colorado, Vereinigte Staaten, 80204
- Rekrutierung
- University of Colorado Denver
-
-
District of Columbia
-
Washington D.C., District of Columbia, Vereinigte Staaten, 20010
- Rekrutierung
- MedStar Washington Hospital Center
-
-
Florida
-
Jacksonville, Florida, Vereinigte Staaten, 32224
- Rekrutierung
- Mayo Clinic Jacksonville
-
Miami, Florida, Vereinigte Staaten, 33136
- Rekrutierung
- University of Miami - Sylvester Comprehensive Cancer Center
-
Orange City, Florida, Vereinigte Staaten, 32763
- Zurückgezogen
- Mid Florida Hematology and Oncology Center
-
Orlando, Florida, Vereinigte Staaten, 32806
- Rekrutierung
- Orlando Health Cancer Institute
-
Tampa, Florida, Vereinigte Staaten, 33612
- Rekrutierung
- Moffitt Cancer Center
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60611
- Rekrutierung
- Northwestern University
-
-
Iowa
-
Iowa City, Iowa, Vereinigte Staaten, 52242
- Rekrutierung
- University of Iowa Hospital and Clinics
-
-
Kansas
-
Kansas City, Kansas, Vereinigte Staaten, 66160
- Aktiv, nicht rekrutierend
- University of Kansas Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02115
- Rekrutierung
- Dana-Farber Cancer Institute
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48109
- Rekrutierung
- University of Michigan Comprehensive Cancer Center
-
-
Minnesota
-
Rochester, Minnesota, Vereinigte Staaten, 55905
- Rekrutierung
- Mayo Clinic
-
-
Missouri
-
St Louis, Missouri, Vereinigte Staaten, 63130
- Rekrutierung
- Washington University
-
-
Nebraska
-
Omaha, Nebraska, Vereinigte Staaten, 68114
- Rekrutierung
- Nebraska Methodist Hospital
-
-
New York
-
Buffalo, New York, Vereinigte Staaten, 14203
- Aktiv, nicht rekrutierend
- Roswell Park Comprehensive Cancer Center
-
New York, New York, Vereinigte Staaten, 10021
- Rekrutierung
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Durham, North Carolina, Vereinigte Staaten, 27705
- Rekrutierung
- Duke University
-
-
Ohio
-
Cleveland, Ohio, Vereinigte Staaten, 44195
- Rekrutierung
- The Cleveland Clinic Foundation
-
Columbus, Ohio, Vereinigte Staaten, 43210
- Rekrutierung
- The Ohio State University Comprehensive Cancer Center
-
Toledo, Ohio, Vereinigte Staaten, 43614
- Zurückgezogen
- University of Toledo Medical Center
-
-
Oregon
-
Portland, Oregon, Vereinigte Staaten, 97239
- Rekrutierung
- Oregon Health & Science University (OHSU)
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19111
- Rekrutierung
- Fox Chase Cancer Center
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15232
- Rekrutierung
- University of Pittsburgh Medical Center - Hillman Cancer Center
-
-
Tennessee
-
Knoxville, Tennessee, Vereinigte Staaten, 37920
- Zurückgezogen
- University of Tennessee
-
Nashville, Tennessee, Vereinigte Staaten, 37232
- Rekrutierung
- Vanderbilt University Medical Center
-
-
Texas
-
Houston, Texas, Vereinigte Staaten, 77030-4009
- Rekrutierung
- The University of Texas MD Anderson Cancer Center
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98109
- Aktiv, nicht rekrutierend
- Fred Hutchinson Cancer Center
-
-
Wisconsin
-
Madison, Wisconsin, Vereinigte Staaten, 53705
- Rekrutierung
- University of Wisconsin - Carbone Cancer Center
-
-
-
-
-
Cambridge, Vereinigtes Königreich, CB2 0QQ
- Aktiv, nicht rekrutierend
- Cambridge Addenbrooke's Hospital
-
Glasgow, Vereinigtes Königreich, G12 0YN
- Zurückgezogen
- Beatson, West of Scotland Cancer Centre
-
London, Vereinigtes Königreich, NW1 2PG
- Aktiv, nicht rekrutierend
- University College London Hospital
-
London, Vereinigtes Königreich, SW3 6JJ
- Aktiv, nicht rekrutierend
- Royal Marsden Hospital - Surrey
-
London, Vereinigtes Königreich, SE1 9RT
- Zurückgezogen
- Guy's Hospital
-
Manchester, Vereinigtes Königreich, M20 4BX
- Aktiv, nicht rekrutierend
- The Christie NHS Foundation Trust
-
Sheffield, Vereinigtes Königreich, S10 2SJ
- Aktiv, nicht rekrutierend
- Sheffield Teaching Hospitals NHS Foundation Trust
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Key Inclusion Criteria:
-
Histologically confirmed locally advanced, metastatic, and/or unresectable GIST. Molecular pathology report must be available for Part 2; if molecular pathology report is unavailable or inadequate, an archival or fresh tumor tissue sample will be required to evaluate mutational status prior to randomization. (GIST 1L Substudy: must have documented mutation in KIT Exon 9 with an available molecular pathology report; archival or fresh tumor tissue sample will be required)
-
Documented disease progression on or intolerance to imatinib (Part 1a, Part 1b, Part 2, DDI Substudy)
-
Participants must have received the following treatment:
- DDI Substudy/Part 1a: Treatment with ≥1 prior lines of therapy for GIST
- Part 1b: Treatment with ≥2 prior TKI for GISTs
- Part 2: Prior treatment with imatinib only
- GIST 1L Substudy: No prior systemic therapy for GIST including adjuvant therapy. Exception: up to 10 participants with ongoing imatinib therapy of ≤4 weeks
-
Have at least 1 measurable lesion according to mRECIST v1.1 (Part1a, Part 1b, Part 2, GIST 1L Substudy)
-
Eastern Cooperative Oncology Group (ECOG) Status
- 0 to 2 (Part 1a, Part 1b, Part 2, DDI Substudy)
- 0 to 1 (GIST 1L Substudy)
-
Have clinically acceptable local laboratory screening results (clinical chemistry and hematology) within certain limits
Key Exclusion Criteria:
- Known Platelet-Derived Growth Factor Receptor (PDGFR) driving mutations or known succinate dehydrogenase deficiency (Part 1a, Part 1b, Part 2, DDI Substudy)
- Clinically significant cardiac disease
- Major surgeries (eg, abdominal laparotomy) within 4 weeks of the first dose of study drug (Part 1a, Part 1b, Part 2, DDI Substudy)
- Gastrointestinal abnormalities including, but not limited to, significant nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude adequate absorption
- Any active bleeding excluding hemorrhoidal or gum bleeding
- Seropositive for HIV 1 or 2, or positive for hepatitis B surface antigen or hepatitis C virus (HCV) antibody.
- Active, uncontrolled, systemic bacterial, fungal, or viral infections at Screening
- Received strong CYP3A4 inhibitors or inducers (Part 1a, Part 1b, Part 2, DDI Substudy)
- Received sunitinib within 3 weeks (Part 1a, Part 1b, DDI Substudy)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Part 1a
Bezuclastinib plus sunitinib 37.5 mg once a day (QD) |
Participants will receive bezuclastinib orally until study stopping rules are met.
Andere Namen:
Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Andere Namen:
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.
Andere Namen:
Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Andere Namen:
Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. |
|
Experimental: Part 2 - Experimental Group
Bezuclastinib plus sunitinib 37.5 mg QD |
Participants will receive bezuclastinib orally until study stopping rules are met.
Andere Namen:
Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Andere Namen:
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.
Andere Namen:
Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Andere Namen:
Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. |
|
Aktiver Komparator: Part 2 - Control Group
Sunitinib 37.5 mg QD |
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. |
|
Experimental: Part 1b - DDI Cohort 1
Bezuclastinib plus sunitinib 37.5 mg QD |
Participants will receive bezuclastinib orally until study stopping rules are met.
Andere Namen:
Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Andere Namen:
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.
Andere Namen:
Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Andere Namen:
Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. |
|
Experimental: Part 1b - DDI Cohort 2
Sunitinib 37.5 mg QD plus bezuclastinib |
Participants will receive bezuclastinib orally until study stopping rules are met.
Andere Namen:
Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Andere Namen:
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.
Andere Namen:
Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Andere Namen:
Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. |
|
Experimental: DDI Substudy (Midazolam)
Midazolam, bezuclastinib, sunitinib |
Participants will receive bezuclastinib orally until study stopping rules are met.
Andere Namen:
Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Andere Namen:
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.
Andere Namen:
Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Andere Namen:
Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. Participants will receive a single-dose of midazolam on Day 1 and Day 15 |
|
Experimental: GIST 1L Substudy
Bezuclastinib, sunitinib |
Participants will receive bezuclastinib orally until study stopping rules are met.
Andere Namen:
Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Andere Namen:
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.
Andere Namen:
Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Andere Namen:
Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Part 1a - pharmacokinetics - Cmax
Zeitfenster: 16 days
|
Maximum plasma concentration (Cmax) |
16 days
|
|
Part 1a - pharmacokinetics - AUC
Zeitfenster: 16 days
|
Area under the plasma concentration-time curve (AUC) |
16 days
|
|
Part 1b - pharmacokinetics - Cmax
Zeitfenster: 14 days
|
Maximum plasma concentration (Cmax) |
14 days
|
|
Part 1b - pharmacokinetics - AUC
Zeitfenster: 14 days
|
Area under the plasma concentration-time curve (AUC) |
14 days
|
|
Part 1b - pharmacokinetics - Tmax
Zeitfenster: 14 days
|
Time to maximum observed plasma concentration (Tmax) |
14 days
|
|
Part 2 - Progression Free Survival (PFS)
Zeitfenster: Approximately 48 months
|
Time from first dose to documented disease progression or death due to any cause, whichever occurs first |
Approximately 48 months
|
|
DDI Substudy - pharmacokinetics - AUC
Zeitfenster: 16 days
|
Area under the plasma concentration-time curve (AUC) |
16 days
|
|
DDI Substudy - pharmacokinetics - Cmax
Zeitfenster: 14 days
|
Maximum plasma concentration (Cmax) |
14 days
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
All Study Parts - observing the safety of each treatment regimen.
Zeitfenster: Approximately 48 months
|
Incidence and severity of Adverse Events from first dose of study drug |
Approximately 48 months
|
|
All Study Parts - observing the safety of each treatment regimen.
Zeitfenster: Approximately 48 months
|
Incidence and severity of Serious Adverse Events from first dose of study drug |
Approximately 48 months
|
|
All Study Parts - observing the safety of each treatment regimen.
Zeitfenster: Approximately 48 months
|
Incidence of Adverse Events leading to dose modifications from first dose of study drug |
Approximately 48 months
|
|
All Study Parts - observing the safety of each treatment regimen.
Zeitfenster: Approximately 48 months
|
Change from baseline in laboratory results |
Approximately 48 months
|
|
Part 1a, Part 1b, Part 2 - Overall Survival (OS)
Zeitfenster: Approximately 48 months
|
Time from first dose to death due to any cause |
Approximately 48 months
|
|
Part 1a, Part 1b, Part 2 - Objective Response Rate (ORR)
Zeitfenster: Approximately 48 months
|
Percentage of subjects who achieved documented complete response (CR) + confirmed partial response (PR) based on modified Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 |
Approximately 48 months
|
|
Part 1a, Part 1b, Part 2 - Disease Control Rate (DCR)
Zeitfenster: Approximately 48 months
|
Percentage of subjects who achieved CR + PR + stable disease (SD) at 16 weeks |
Approximately 48 months
|
|
Part 1a, Part 1b. Part 2 - Time to response (TTR)
Zeitfenster: Approximately 48 months
|
Time from first dose to first documented response based on modified Response Evaluation Criteria in Solid Tumors Version 1.1 |
Approximately 48 months
|
|
Part 1a, Part 1b, Part 2 - Duration of Response (DOR)
Zeitfenster: Approximately 48 months
|
Time from first response (CR or PR) to the date of progression or death from any cause, whichever occurs first |
Approximately 48 months
|
|
Part 2 Only - European Organisation for Research and Treatment of Cancer Quality of Life (EORTC-QLQ-30)
Zeitfenster: Approximately 48 months
|
Change in individual scores in patients with locally advanced, unresectable, or metastatic GIST treated with CGT9486 in combination with sunitinib compared with patients treated with sunitinib monotherapy. The scale comprises 30 questions, 24 of which are aggregated into 9 multi-item scales, to include 5 functioning scales (physical, role, cognitive, emotional and social), 3 symptom scales (fatigue, pain and nausea/vomiting) and 1 global health status scale. The remaining 6 single-item scales assess symptoms (dyspnea, appetite loss, sleep disturbance, constipation, diarrhea and the financial impact). All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning, while higher scores on the symptom and single-item scales indicate a higher level of symptoms. |
Approximately 48 months
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Pathologische Prozesse
- Neubildungen
- Neubildungen nach histologischem Typ
- Gastrointestinale Neubildungen
- Neoplasmen des Verdauungssystems
- Erkrankungen des Verdauungssystems
- Magen-Darm-Erkrankungen
- Neoplastische Prozesse
- Neubildungen, Binde- und Weichgewebe
- Neubildungen, Bindegewebe
- Pathologische Zustände, Anzeichen und Symptome
- Neoplasma Metastasierung
- Gastrointestinale Stromatumoren
- Heterocyclische Verbindungen, 1-Ring
- Heterocyclische Verbindungen
- Heterocyclische Verbindungen, 2-Ring
- Heterocyclische Verbindungen, Fusionsring
- Azolen
- Indolen
- Benzazepines
- Pyrrolen
- Benzodiazepine
- Sunitinib
- Midazolam
Andere Studien-ID-Nummern
- CGT9486-21-301
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .